Is AOD-9604 Legal in Ohio? How to Access It Legally

What AOD-9604 Actually Is

AOD-9604 is a synthetic peptide fragment corresponding to amino acids 176 through 191 of human growth hormone (hGH). Researchers at Monash University in Australia developed it in the 1990s with the goal of isolating hGH's fat-burning properties while eliminating the insulin-resistance and proliferative effects associated with full-length hGH. The company Metabolic Pharmaceuticals advanced it into clinical trials targeting obesity.

Mechanism of Action

The peptide binds to beta-3 adrenergic receptors in adipose tissue, stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat synthesis). Unlike intact hGH, AOD-9604 does not significantly raise IGF-1 levels or affect blood glucose in the doses studied clinically. A 2001 study published via ClinicalTrials.gov and related Metabolic Pharmaceuticals data showed that the peptide produced statistically significant reductions in body fat in rodent models before human trials began.

Clinical Trial History

Metabolic Pharmaceuticals ran multiple human studies between 2001 and 2007. The trials tested oral AOD-9604 at doses ranging from 1 mg to 10 mg daily over 12-week periods in overweight and obese adults. The phase IIb trial enrolled 300 participants. Results were modest. The drug did not meet the primary weight-loss endpoint required for FDA approval, and Metabolic Pharmaceuticals discontinued the obesity program. The FDA has not approved AOD-9604 for any indication. You can review the registered trial records directly at ClinicalTrials.gov.

Federal Legal Status of AOD-9604

AOD-9604 is not approved by the FDA as a finished drug product. It is also not listed as a Schedule I through V controlled substance under the Controlled Substances Act, which is administered by the DEA. The full current schedule of controlled substances is maintained at the DEA Diversion Control Division and is cross-referenced through the FDA Drug Databases.

The FDA Bulk Drug Substances Lists

This is where the regulatory complexity becomes concrete. The FDA regulates compounding pharmacies under two statutory frameworks.

Section 503A covers traditional compounding pharmacies that prepare medications for individual patients pursuant to a valid prescription. Under 503A, a pharmacy may compound using bulk drug substances that appear on the FDA's affirmative "bulks list", or substances that were used in FDA-approved drugs, or substances that are components of approved drugs. AOD-9604 does not appear on the current FDA 503A Bulks List. As of 2025, it has not been nominated to that list and formally evaluated.

Section 503B covers outsourcing facilities, which can produce larger batches without individual prescriptions. The FDA 503B Bulks List also does not include AOD-9604.

The FDA's guidance on compounding makes clear that compounding bulk substances not on either list carries regulatory risk for the pharmacy. The agency can take enforcement action against pharmacies compounding such substances.

FDA Enforcement Posture on Peptides

The FDA sent warning letters to compounding pharmacies regarding several peptides in 2022 and 2023. AOD-9604 was not named in those specific letters targeting BPC-157 or certain other peptides, but the enforcement climate has tightened. The FDA's import alert system covers unapproved new drugs. Compounded AOD-9604 technically qualifies as an unapproved new drug under 21 U.S.C. § 321, meaning the FDA could take action at any time. Patients and prescribers should treat this as a genuine, not merely theoretical, risk.

Ohio State Law and the Ohio State Board of Pharmacy

Ohio does not have a state-level statute that independently bans AOD-9604 or peptides as a class. The Ohio Revised Code governing pharmacy practice (ORC Chapter 4729) and the Ohio State Board of Pharmacy rules largely track federal law on compounding. The Ohio State Board of Pharmacy enforces compliance with both state pharmacy rules and federal compounding frameworks, including the Drug Quality and Security Act.

Ohio's Medical Practice Act

Under Ohio's medical practice act (ORC Chapter 4731), a licensed physician may prescribe any substance within the scope of legitimate medical practice, including compounded medications. The physician must document a valid patient-provider relationship, a clinical rationale, and informed consent. Ohio's medical board has not issued a specific advisory banning AOD-9604. The absence of an explicit prohibition is not the same as affirmative approval. Physicians prescribing AOD-9604 in Ohio operate under general professional standards and assume prescribing liability in a context of federal regulatory uncertainty.

What Ohio Pharmacies Can Actually Dispense

An Ohio-licensed 503A compounding pharmacy could, in principle, compound AOD-9604 from bulk substance with a valid prescription. The pharmacy must source the bulk substance from an FDA-registered manufacturer and must be confident it is not violating the FDA's interpretation of allowable bulk substances. Given that AOD-9604 is not on the 503A bulks list, a pharmacy compounding it accepts some degree of FDA enforcement risk. Patients should ask any pharmacy directly whether they have legal counsel confirming their AOD-9604 compounding is defensible under current FDA policy.

How to Access AOD-9604 Legally in Ohio

The only access path that carries any legal defensibility for an Ohio patient involves three steps: a licensed physician, a valid prescription, and a pharmacy operating under 503A or 503B rules. Each step has specific requirements.

Step 1: Establish Care with a Licensed Ohio Physician

A physician licensed under ORC Chapter 4731 must evaluate you in a genuine patient-provider relationship. Telehealth is permissible in Ohio for established relationships; Ohio House Bill 341 (2021) expanded telehealth prescribing rights. The physician must document a clinical indication. For AOD-9604, that indication typically involves body composition goals, excess adipose tissue, or metabolic concerns. The physician should review your current medications, thyroid function, metabolic panels, and body composition data before prescribing.

Step 2: Obtain a Written Prescription

The prescription must specify the patient's name, the prescribing physician's DEA number (even for non-controlled substances, many pharmacies require this for verification), the compound name, dose, route, quantity, and instructions. The physician should also document informed consent explaining that AOD-9604 is not FDA-approved, that compounding carries manufacturing variability, and that long-term safety data in humans are limited.

Step 3: Use a Verified Compounding Pharmacy

The pharmacy must be licensed in Ohio or licensed in another state with authority to ship into Ohio. Patients should confirm the pharmacy is accredited by the Pharmacy Compounding Accreditation Board (PCAB), which is a voluntary but meaningful quality signal. The pharmacy should provide a Certificate of Analysis (COA) from a third-party lab confirming peptide purity and the absence of contaminants. Research published in the context of compounded drug quality standards consistently shows that third-party analytical testing improves product reliability, as noted in FDA guidance documents on current good manufacturing practice for compounding pharmacies.

What to Avoid

Purchasing AOD-9604 from research chemical websites, overseas vendors, or any source that does not require a prescription carries significant legal and safety risk. The FDA has authority to seize unapproved new drugs at the border under its import alert powers. Products sold "for research use only" are not intended for human administration under federal law. An FDA import alert can apply to such shipments.

Clinical Evidence: What the Research Actually Shows

The clinical evidence base for AOD-9604 in humans is limited and dates primarily from the early 2000s. Understanding the evidence accurately matters for both patients and prescribers.

Efficacy Data

The phase IIb study by Metabolic Pharmaceuticals, conducted across Australian sites, tested oral AOD-9604 at 1 mg daily versus placebo in overweight adults over 12 weeks. The treatment group showed modest reductions in body fat mass compared to placebo, but the effect size did not reach the threshold the company needed for a regulatory filing. No published peer-reviewed trial has demonstrated statistically significant, clinically meaningful weight loss in humans from AOD-9604 alone at doses studied to date.

Animal studies, including rodent models published in reference databases at PubMed, have shown more consistent lipolytic effects. The gap between animal and human data is a recurring theme in peptide development. Clinicians reviewing AOD-9604 for patients should reference the NIH's guidance on interpreting preclinical data when counseling patients on realistic expectations.

Safety Profile

The phase II human trials did not reveal significant adverse events at 1 mg oral daily doses. The peptide did not raise blood glucose or IGF-1 in a clinically meaningful way at those doses. However, the injection doses used in current compounding practice (typically 200 to 300 mcg subcutaneous daily) differ from the oral doses studied clinically, meaning the safety database for the injectable form comes almost entirely from post-marketing clinical experience rather than controlled trials. The FDA's framework for evaluating drug safety requires controlled evidence the current AOD-9604 literature does not fully provide.

Comparison to Approved Weight-Loss Options

FDA-approved weight-loss pharmacotherapy provides a useful benchmark. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg subcutaneous weekly produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [published in the New England Journal of Medicine, doi:10.1056/NEJMoa2032183]. AOD-9604 has no comparable trial. That gap in evidence should inform any honest clinical discussion about peptide therapy versus approved agents. The Endocrine Society's clinical practice guidelines on obesity pharmacotherapy, available through academic.oup.com, do not include AOD-9604 among recommended agents.

Physician and Pharmacist Perspectives on Prescribing AOD-9604 in Ohio

Prescribing physicians in Ohio who work with peptide therapies generally take one of two positions on AOD-9604.

The first group prescribes it within a documented clinical framework, citing the absence of a federal scheduling designation, the absence of an Ohio-specific ban, and what they characterize as a reasonable safety signal from the clinical trials. They typically combine it with dietary intervention and metabolic monitoring. They document informed consent carefully.

The second group declines to prescribe it, citing the FDA's compounding enforcement posture and the limited human efficacy data. Several clinicians in the functional medicine space have noted publicly that they shifted away from AOD-9604 after the FDA's 2022 to 2023 peptide enforcement actions, preferring peptides with stronger regulatory footing.

As of 2025, the American Association of Clinical Endocrinology (AACE) has not issued a formal position statement on AOD-9604. The Endocrine Society similarly has not endorsed it. The absence of professional society endorsement does not make prescribing illegal, but it does affect the defensibility of a prescriber's clinical decision-making in a liability context.

Monitoring Recommendations if You Are Prescribed AOD-9604

If a physician does prescribe AOD-9604 in Ohio, monitoring should follow a structured protocol. The following parameters are reasonable based on the drug's proposed mechanism and general peptide prescribing standards:

• Baseline fasting glucose and HbA1c, repeated at 12 weeks
• IGF-1 level at baseline and 12 weeks (to confirm absence of IGF-1 elevation at prescribed dose)
• Body composition measurement (DEXA or validated bioelectrical impedance) at baseline and 12 weeks
• Liver function panel at baseline
• Injection site inspection at each follow-up visit

The American Diabetes Association Standards of Care and the CDC's guidance on metabolic monitoring provide useful frameworks for interpreting glucose and HbA1c changes in the context of any weight-management intervention.

A 12-week trial is a reasonable evaluation period. If no meaningful change in body composition is documented by DEXA or validated measurement at 12 weeks, continuation is difficult to justify clinically or from a cost-benefit standpoint.